N
Google TrendMAX CASTER (200+) — Moose Def. Max Caster At TNA Bound For Glory 2026
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:max caster200+prince harry family photo story200+kelley knockel500+torino vs udinese200+coventry vs newcastle5000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Real-World Multiple Myelo" (30 stories)

Top Headline Story

IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
Lead StoryCancerNetworkgeneral
Oct 1

IMS 2026: Key Updates Across The Multiple Myeloma Paradigm

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPMUtKRHl2alp2cm53UnZCdnFyamhOLVdEd0MxWG1tTVA5cnlMX1puSkFDd0oxdlR4cjNyUi1UdEZXWVFKVFJDbTZpLUJWOHk4VmpsVzJRSzU2dzNuaFRKUndFZVFucWF5ekpJblRPUmZwbTgxYUZGenNhaXhLWUJDb1BhSzVQX1Z3bkJ5dEVXT1pqMXhxbmRn?oc=5" target="_blank">IMS 2026: Key Updates Across The Multiple Myeloma Paradigm</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+18m ago

max caster

Moose Def. Max Caster At TNA Bound For Glory 2026

Filter stories
200+18m ago

prince harry family photo story

Prince Harry Reveals the Photo He Took of Archie and Lilibet That ‘Fills My Heart’

Filter stories
500+28m ago

kelley knockel

1 dead, multiple injured after pair of motorcycle crashes involving deer in Iowa

Filter stories
200+28m ago

torino vs udinese

Torino vs Udinese: Italian Serie A stats & head-to-head

Filter stories

Search Results for "Real-World Multiple Myelo"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal
Natureworld

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0yNktMcld5Y2ljeFg0WU1EVXVOdk9FUERsVDlpVTBfQ3JQY0tESEFYZkhIYjVyMGtKdlNKRk5PSVU3b2ZYc3kxN2xSZldzRUZOUWhYNVlEckE4dlEwOFQw?oc=5" target="_blank">Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World Data Show Carfilzomib Regimens Deliver Strong Results in Multiple Myeloma
Bioengineer.orgworld

Real-World Data Show Carfilzomib Regimens Deliver Strong Results in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOVWV1XzlsTWJyQlFxNUFUOVdzMTJ3ZFYwek0wNnRNeFJpM3JFVVVwbDFYczRMaE1jeVUwVnJTblF2MGQyd1l0WnpZcVFLQ29fNm53c01SNy04M0JkNlBJY1BFWjBXdzhCRnh0VFRsakZ2WmQ4RXdFVk9wa2RFNUZteGtDaWtKeFBfZ1Z3MmZGeHZWOFZ4UG5MNU4yaHRYMG5WZWN2QTNHYlBWRTIyc3c?oc=5" target="_blank">Real-World Data Show Carfilzomib Regimens Deliver Strong Results in Multiple Myeloma</a>  <font color="#6f6f6f">Bioengineer.org</font>

Read Full StoryMore like this
Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials
Targeted Oncologyworld

Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZ0RxZ083YXpxVlBHeU5YblVhd1RxNDFlOE5nd1lxZ2I1LWRBdjNmRkpSc1c0MGRGM3gtNHpmUXNHQW5Zd3hhbmstT0tqck0ybm9jbmVlVGpyREhZWFdXVG9ZcEU3Y2hfbUVtWEpSek14RUVmT1A2UUcxalZ2ZWlma1UwbmsyUFZadnk2U09JRXE2NU1aeFFWZXAwZDVab3dldjk4S1Q5Y20?oc=5" target="_blank">Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
How effective is elranatamab for treating multiple myeloma in the real world?
Fred Hutchinson Cancer Centerworld

How effective is elranatamab for treating multiple myeloma in the real world?

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPWldkWklhVXlRTmo1RFlJSXBvN3pIbkNyTHRzLWtLeDNlUGVSNlFycTBlLS1tQkoxZmY2OFFieVh3NTRFX09ZTDZVNm5zdDh0VmVpYUxIZHl0TmZ5aDBzNmY3TDNyTzl5a1FWS2NWZDQzeVREYlZqX2hqMmYtQU1IVU5NTGhadWxrR1E?oc=5" target="_blank">How effective is elranatamab for treating multiple myeloma in the real world?</a>  <font color="#6f6f6f">Fred Hutchinson Cancer Center</font>

Read Full StoryMore like this
Balancing Clinical Trial and Real-World Evidence in Multiple Myeloma
OncLiveworld

Balancing Clinical Trial and Real-World Evidence in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNM2pmd2ZsUGdiY1JLWV9JQlAtTUs5NHltSXYyNkhrcGxuUERnSFhxZWQ0eHlSZ0ozcXZyME5pTm8tWDZLTVNRODNzTms0NE5rY2hGREVYMTRpWEVwSndOb0FlN0tVLUZJVlcxWkIwNnJib2s3WWhKRlFMZ0Jlb2tsRElfTk5TcVVJSkdCX2tfZEpyYmdvQThZb2MxTUVFZw?oc=5" target="_blank">Balancing Clinical Trial and Real-World Evidence in Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center
Frontiersworld

Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQekRvak1Ua2NyMTNlMUI4VWEzUWJBQUxsM3dHZ2QwOEFSUFRzQmw4MnZfY3JtSEt3ZklLbm8wNElnOVpuQjNRMGhFT1JUTlQ3WVV2QmNCRFVkSy11cEYzdlQ2blJYRkFFdXVyVVNELUNDU3lIMW9OandBSXYxRFZWZGllVzFOM2hQT1M4TDFB?oc=5" target="_blank">Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab
The ASCO Postworld

Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOb011cURwb3AzZ0g1QUExUmNYcDhkNXliWEZZZWptMDk3QjRteEU1QUszbDNWLTNyQkN5VWEzaW1KdXVQVGpIT2xpb21ZM0tIY1c2QWJ0cmF6eWZXZVJPV2RFV2dZN3ZpOExXOEIwZjk0bnNnNGEtTnZTeXhxQl9Ta3NhVWZMakVqX0l4Sl9NVndpNW9yVVE?oc=5" target="_blank">Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
Natureworld

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE10c3lGVGZfdVFXNVI0bGhwZW9XVkxVVldSakxncEFXcjk1Z0JXb283MDdnVDYzdG9NZEM1dkpWOU4tWXB5amtEVFk4MklhNGJla2JFQXZsSllnWFYzU19z?oc=5" target="_blank">Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
Targeted Oncologyworld

What Long-Term Real-World Data on CAR T in Myeloma Could Reveal

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNOWtXd0pJN3RIS3dqRDNIWkU4dXQzb1dvbDcyT2xzc002Rl9lajBjcGtEc0dMZVpoYURqcFVfSVF6N1UzQlA3bXZya1R4aGdKaFhGSXVKdmtlbEFGM2dRTTRicERFcGlrOGpVYTI3S3lQRjJMUVhPQ2Y4TjB1SEhEOWE5UlFmdWlONFZGd0JZLXM4YXVsb20ydGhjMTA?oc=5" target="_blank">What Long-Term Real-World Data on CAR T in Myeloma Could Reveal</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?
CancerNetworkpolitics

Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNNDgweUxiUXNQbFV3QlA2cWxBTjFGdWIxMWs5RWJpWFFfTVllNW1oeFdsVUJNNmQtV0xLa1FmYkhWM194cXlRRnJaWjNGVmxqekJPbXFaem1VSnpsYkJfMGc0WFIwMnd3ZS1BTGx5SENrdy0zVExRN016Z29OQ3BkNHN5S3BZQzNfMlNvREl0aWthc05jMTlHRUY4NkxxVTBFelpF?oc=5" target="_blank">Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Dr Biran on the Real-World Performance of SKY92 Gene Expression Profiling for Risk Stratification in Multiple Myeloma
OncLiveworld

Dr Biran on the Real-World Performance of SKY92 Gene Expression Profiling for Risk Stratification in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQZlNyb2tCbWlLZFlUMHlSLUx2WDVpTDdFUTNNWnZlWWNlWTRROHRDSGFqbVFjR3Z6MlBnVjNmSlZSd1Z3NzhHOEV5Z3YteE5sZ1BQN0JoYWFNbXpRS0pvazdfZmxDbzZLdlNDWlFXRVFsM1NQOHYyemdHME9ZXzNFc3RwX1RyYllxSTNlTDM5QlFoc0dWMk5rQTlLeFhUTGlnektQendzUE9xanUwemV1Rmg0WDFNWmh6eFhfOXBpOVB0XzAtN2RnVW9tclNTdWx0ZWY1WEFQaXNwdERCeDhZ?oc=5" target="_blank">Dr Biran on the Real-World Performance of SKY92 Gene Expression Profiling for Risk Stratification in Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Natureworld

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5zcG5uYV9KM1NNQ0JQUnVoZmdFT01xWC1nVXRjUGVlc0pEMDBzZFBzZVNkYlpKWTh3NEg1ZUcyWXRwcXdWR01IT1JqOG9MeElLSW9QWkU5QWoyUGFMR2xr?oc=5" target="_blank">Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma
Targeted Oncologyworld

Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPY0hPTDZkckVqX3pMcU5uZDl3bW5PLVhGYzhGTzJDN0ZlTnR1VGdqUG9mTmxwdzVBNW5URktOb1JCcE1iWGpKNklDVXBZc0NTRU9kb3BNc3VnRjBYR1I3NVIyZmtJZHVveWczYmZUVEx3SjBVZDRjN1F0Z1EySDhtNW5qWnNFYzNSRnQ4Y1o3V0dwUjZnMUJuZGV2QXQzQzRYc0hsOVJuVTZpLTNTOFE?oc=5" target="_blank">Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Rethinking the “Next Line” in Relapsed/Refractory Multiple Myeloma: Why Using CAR T-Cell Therapy Earlier Matters
OncLivegeneral

Rethinking the “Next Line” in Relapsed/Refractory Multiple Myeloma: Why Using CAR T-Cell Therapy Earlier Matters

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNN3JHcGFteTg1ZmZUZmRaMnp4bXVkejl1eFpuNTVyVGhKNW5uWXZJVzhkNUJPZ2tpcllOR3cxcFhxd1d2V3dfbHVVVE1CUno2eWlpcExJd05EWEdhZVh2UnZZVmdlblVnMnRxZFM2MzBCcmlzWkw3bXUzVTVyVEtOVmRPSDR1QmlzUGlJNDZBd05tdElibDExY2hWbTdEcEpzMldfajlJRXZnOUVYcTBjaVVQZlpqc19raWhQUUFsV0ZnRU5XUFg0UzRLX1JfQmRYQ1lJWA?oc=5" target="_blank">Rethinking the “Next Line” in Relapsed/Refractory Multiple Myeloma: Why Using CAR T-Cell Therapy Earlier Matters</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Development and multinational validation of a multiple myeloma–specific comorbidity index using real-world cohorts: CAREMM-2108
Natureworld

Development and multinational validation of a multiple myeloma–specific comorbidity index using real-world cohorts: CAREMM-2108

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE12Zy1SWkREeGNDb25WQlpfMlZjTW9ocHUyVklaemNxSHB4QWhtSmhlSHJsOENtZDRhcEVoTWJ2SGlqaGVWcFJ3NUx4THZBZm9SUF9YN3dYQzduVzh0a1lz?oc=5" target="_blank">Development and multinational validation of a multiple myeloma–specific comorbidity index using real-world cohorts: CAREMM-2108</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Examining Real-World Approaches for GPRC5D Bispecific in Multiple Myeloma
Targeted Oncologyworld

Examining Real-World Approaches for GPRC5D Bispecific in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMmotRnJHLWw3d1FLeUZjUDVRbHlmeFlTdDlRYzJpNUxvNEV4NlFWRHUxVHIyUUxYREhka3h0TTBTMzIxN1kzbmU2aGtYSTNYZW9FQ1BoZFR0QWEtQTBYdDN3cGJaSFY2MzFKVnprWFN2cWphWGhBZWZIYXhqSFlROFJLNEM2SnZZSzZYNkh0U1BqYlh6ekhtMUlqWWRxNGNZTkltb1ptNkJXQQ?oc=5" target="_blank">Examining Real-World Approaches for GPRC5D Bispecific in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry
Natureworld

Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB2TG0tS3ZILUtwZXAxSnF2NG95MldEMDdyUnU2TUdXNmJvejBZeGpWdm1QcWp3WmRua2puRy15TzZNRHBncDM4cGIxdlpaQW9GVDJtT2pkZGtTbWFZSXhZ?oc=5" target="_blank">Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Teclistamab Maintains Activity in Heavily Pretreated Real-World Myeloma
Targeted Oncologytech

Teclistamab Maintains Activity in Heavily Pretreated Real-World Myeloma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPLVVTSWR4YzVRTVZPdjFnMnhLWFg0WkxSdHFqdUR1V0IyN2trTGRhc3VBcUJTdmpXSlNnMUZUdWFrN2RaT1N4aUxnR2dwX3dpdG45ZnoyWWtLaE0ydmFyb1lnRnpaTmxMd29mMF9rbVY4TnRuZ2Jua2UtUUNLUHJxQS0yOUtmM2hrVnJfdEFQeGM3b2JZaHJDOVFvY1FuR2NJaGhRNFNwUQ?oc=5" target="_blank">Teclistamab Maintains Activity in Heavily Pretreated Real-World Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium |
Natureworld

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium |

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3d2FLT0NXQnh0cUNEVFdnaEo5cnQ2c3ZjUTNQMmtfUnhDQ3oycW9hOHVNMHlUUmowMVVYUGRvZWV6cnMyS3NzcEVCM0UyQ0tuMmF3NkxFU3Q2MmJyWmRJ?oc=5" target="_blank">Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium |</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy
CancerNetworkgeneral

Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQUklDdHNRbC1IWXNHcTFhUnJWMXZJSWRYNHpGNWZsY2JyNXB2bjl6TnR5VzdlTm9sN1R2YUE1VXpZTGo3NHYzTlB6d1dxYVVGVi1jTUdNS3VKU3U4empGc1FfVVdtTVRkT1YweUluc2RPZ1VVU0lCNUlKMmdJakpRZWlQS1lmNEE3Skk3N25naUYxM1JwSVppa2FDNUJEeC1UUUxfenc4WVd2VFc0OVJkcVgtZGlKdVdIVjYzcUdXalE5cE5vNjh0VEU2NlI?oc=5" target="_blank">Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Talquetamab in R/R Multiple Myeloma: Real-World Analysis From the IMWG Immunotherapy Registry
Oncodailyworld

Talquetamab in R/R Multiple Myeloma: Real-World Analysis From the IMWG Immunotherapy Registry

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5LTkprRGhfRlNpR1BJMy10TVZweFhmXzZmSS11alZGcF9rNHhBdEFKNW00TGRwX29BUThDNDM4Mk9HcUl4MWJxeVRGVkRpOU45YTJuSVVDb3hHaGVsQjF6TWlVUXptNnJnRWp2LW42RjhjTFhhUUR5QmpUTW1EUQ?oc=5" target="_blank">Talquetamab in R/R Multiple Myeloma: Real-World Analysis From the IMWG Immunotherapy Registry</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma
CancerNetworkgeneral

Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQeTlRcF9UcFVtVVFoczRiTWVZaEtZWnA5Y3NKT0lfMk1TMHAwelpEdE5qaTI2bm9BdUd2NF9FMmNNX2VXWkpIT09sZm9RM01uSnNtX1hjaS16N0NkWngtZ1VNYnBsZm53cm9xTGNSMHJYdXM5MTVLWjBjN25rSFVGUmxMTUh4NDV6Nk9mdjRMbWR3cUVUdlNTRWIyRm9NRGZoa19Ga3pVVQ?oc=5" target="_blank">Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies | Blood Cancer Journal
Natureworld

Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1TTm5hN2loQmlLQU5GRU5ncTZZMWJEcXVTVFRKNlRoTElUNGVPU2R6LTJyTHN0YlUtNWQyRi1ITlZpT0dHY2s4aFk1RUVuc2U0XzFRZUVUWk1HUEIxR2FB?oc=5" target="_blank">Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
CancerNetworktech

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQTHBsa3E0QjlvNkl6MHU3eHc4ZWpQOTRQZVVucXpndmtkS2EwYUtGaTN2UGVhNnRRNWRUOUpwb3dtX1NPWmRiMHZhdHlJaWprVTN6cjVZdGpZcFV0NnNkWWIxamhZaHJZeGNDSl81YlZpOTJIaER6SUxTOENRcVJWdlFlS09ZRWxxYW84QkNzS0NOLXFEVVNCU0dzaDU3cDJ5VkJmZktEeVc0bVNVM2FON08xVGUwUQ?oc=5" target="_blank">Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal
Natureworld

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA3MzNqeV80enZnNDY5QXczckY5SEJoOWZwYXdLbUNraGtXQ3Bscy1tbVFYMUg2Z05xYkljNWt6MkpfaUxPcmRRbHdPVzVja2lHRVY3cDNabG5vRUwzVFdZ?oc=5" target="_blank">The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
Naturegeneral

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?
CancerNetworkgeneral

Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNa1ZjTllmN2tIb0FOOVhPSzVzUkZVRzktWkg5dzZJNjJrcXlBci12WXNHaTg1NGYzbEFLMUpnUUVaNDRYcnNPczRrbzZmb19IeWx6aVJrRkZlTHowU21hUWd2UFhtaVptZWNEN2c5YS1nd3g0cU9BLWN5RUkxSU9EZzRVZzZsa2lPT2lDSVZDU2tmaDZ5V3ZVZm9oVVlfUTRiZ00wRjdMQlJsLXMwLTc2Y0g4WnBGZ3ZVU3FvcUdDUQ?oc=5" target="_blank">Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma
AJMCworld

Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOek1NR2VhdkFBSnhXWnRaSFhqX2tCYkRaTllrT2pBdlpCSk5McW5fQWZYWjI4cG9ial9aNERNLW5UR3JiTUxQUUdXWjlBYzVkRWFKXzRLRWxicHU5NkpNRENuN29mSjlHZDhHY3RWaHJlS0JLdHprbDVSUFZLcG1GN2l0Vm9Tb2NaTTI1SlRpWFo0a3dmWVcxTURlUFJLWEdYbFNFcWV5TmFVWlpGQ0hHWHphYXVkUmhXMVhHMU1qNERNVWs?oc=5" target="_blank">Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT
Naturegeneral

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE82QWp4M2J1UFhZOTh0eGphNkdvc0VqRmlMRm1LcVp1aGRaazdIbHVlcVlGcURQX2pBcW1RdVNZcWpGNkJiU3BHbDU5QUdrUUNYeTBoeVFUNjNQXzZ0bnQ0?oc=5" target="_blank">Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Real-World Multiple Myelo" — Live Google News Trends & Headlines